Unlike the majority of persisters (noncycling persisters) in lung cancer cells with EGFR mutation undergoing EGFR tyrosine kinase inhibitor (Osimertinib) treatment, this rare lineage not only emerges but also continues to proliferate under drug pressure instead of remaining arrested. This evidence concerns the gene EGFR and lung carcinoma.